In this study, MS-20 treatment in combination with an anti-PD1 antibody effectively inhibited tumor growth, increased the abundance of total and activated CD8+ T cells and inhibited PD1 expression in the tumor microenvironment in animal models. Here, CD8A is linked to neoplasm.